OptiNose Past Earnings Performance
Past criteria checks 0/6
OptiNose has been growing earnings at an average annual rate of 16.1%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 26.6% per year.
Key information
16.1%
Earnings growth rate
31.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 26.6% |
| Return on equity | n/a |
| Net Margin | -50.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How OptiNose makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 71 | -35 | 80 | 5 |
| 30 Sep 23 | 72 | -41 | 84 | 7 |
| 30 Jun 23 | 72 | -46 | 92 | 9 |
| 31 Mar 23 | 73 | -68 | 101 | 12 |
| 31 Dec 22 | 76 | -75 | 108 | 15 |
| 30 Sep 22 | 78 | -75 | 111 | 18 |
| 30 Jun 22 | 80 | -77 | 111 | 21 |
| 31 Mar 22 | 77 | -82 | 109 | 25 |
| 31 Dec 21 | 75 | -82 | 107 | 25 |
| 30 Sep 21 | 68 | -91 | 108 | 27 |
| 30 Jun 21 | 62 | -95 | 107 | 26 |
| 31 Mar 21 | 54 | -97 | 106 | 24 |
| 31 Dec 20 | 49 | -100 | 105 | 23 |
| 30 Sep 20 | 44 | -101 | 104 | 22 |
| 30 Jun 20 | 41 | -109 | 105 | 21 |
| 31 Mar 20 | 37 | -110 | 105 | 21 |
| 31 Dec 19 | 35 | -110 | 104 | 21 |
| 30 Sep 19 | 27 | -111 | 101 | 19 |
| 30 Jun 19 | 16 | -108 | 98 | 16 |
| 31 Mar 19 | 11 | -105 | 94 | 13 |
| 31 Dec 18 | 7 | -107 | 96 | 10 |
| 30 Sep 18 | 4 | -101 | 90 | 8 |
| 30 Jun 18 | 2 | -93 | 75 | 12 |
| 31 Mar 18 | 1 | -81 | 57 | 14 |
| 31 Dec 17 | 0 | -62 | 32 | 17 |
| 30 Sep 17 | 0 | -43 | 15 | 19 |
| 30 Jun 17 | 0 | -35 | 10 | 16 |
| 31 Mar 17 | 0 | -46 | 8 | 15 |
| 31 Dec 16 | 48 | 2 | 7 | 15 |
| 31 Dec 15 | 0 | -40 | 6 | 22 |
Quality Earnings: 0OP is currently unprofitable.
Growing Profit Margin: 0OP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0OP is unprofitable, but has reduced losses over the past 5 years at a rate of 16.1% per year.
Accelerating Growth: Unable to compare 0OP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0OP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 0OP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.